medigraphic.com

2023, Number 4

<< Back Next >>

Rev Educ Bioquimica 2023; 42 (4)

Quemerina: un posible biomarcador del procesoproinflamatorio en tejido adiposo blanco

Manivel CRA, Sánchez VR, Ramos RM

Language: Spanish
References: 31
Page: 187-195
PDF size: 628.47 Kb.


ABSTRACT

Chemerin is an adipokine secreted by white adipose tissue, and is respon-sible for regulating different biological processes such as adipogenesis, angiogénesis, and metabolism. In addition, it acts as a proinflammatory agent, favoring the development of obesity. Experimental evidence shows an association between its serum concentration and the development of an inflammatory state, overweight, obesity and associated pathologies such as cardiovascular disease, type 2 diabetes mellitus, and hypertension, among others. This raises the possibility of using chemerin serum levels, in conjunction with a medical evaluation, in the timely diagnosis of overweight and obesity. The aim of this work is to analyze the role of chemerin in the initiation and development of the inflammatory process and its possible utility as an early overweight and obesity biomarker.


REFERENCES

  1. Maldonado Vega M, Calderón Salinas J.C. Eltejido adiposo y la respuesta de macrófagos enel proceso inflamatorio y resistencia a lainsulina. REB. 2022; 41(1):3-17.

  2. Frigolet E, Gutiérrez R. Los colores del tejidoadiposo. Gaceta Médica de México. 2020;156:143-150.

  3. Alcalá Hernández C.F, De la Rosa L.A, WallMedrano A, López Días J.A, Álvarez Padilla A.Avances en terapia farmacológica y fitoquímica de la adipogénesis. Nutr Hosp. 2015; 32(2):545-555.

  4. Paul A. Adipose Tissue heterogeneity:development and application of nonlinearmicroscopy methods. [Tesis de doctorado].Gothenburg, Suecia: Universidad deGothenburg; 2018. p. 9.

  5. Vega Robledo G. B, Rico Rosillo M. G. Tejidoadiposo: función inmune y alteracionesinducidas por obesidad. Rev Alerg Mex. 2019;66(3):340-353.

  6. Torres Valdez M., Bermúdez Pirela V.J.Metabolic changes in obesity. En: Mcfarlan S.I,Editors. Obesity- Recent Insights andtherapeutic Options. Intech Open. 2023. [citado25 feb 2023]. p. 1-19. Disponible en:https://www.researchgate.net/publication/370044592_Metabolic_Changes_in_Obesity

  7. Banegas H.D, Medina L. F, Medina M. F,Montencinos L. F, Quintanilla G. J, Aceituno N.Tejido adiposo y su función endócrina. RevistaCientífica de la Escuela Universitaria de lasCiencias de la Salud. 2019; 6(6):49-60.

  8. Rodríguez Trujillo J. Adipocinas y marcadoresclínicos periodontales como indicadores deriesgo en pacientes con artritis reumatoidetemprana. [Tesis de licenciatura]. Bogotá:Universidad del Bosque; 2019. p. 17-19

  9. González-Ponce F, Flores Chávez A, RamírezVillafaña M, Pérez Guerrero E, RomeroMoreno J.R, Saucedo Ulloa M, Aguirre RomoA, Huerta Viera M, Trujillo Trujillo X,González López M. Quemerina en síndromemetabólico. El Residente. 2015; 10(3):125-131.

  10. Ibrahim D. L, Taha M. E, Kamal A. M.Evaluation of adipokine chemerin inhypertensive obese. Biosci J. 2019; 35(6):1958-1967.

  11. Helfer G, Quin Feng W. Chemerin: amultifaceted adipokine involved in metabolicdisorders. Journal of Endocrinology. 2018; 238:R79-R94.

  12. Yu M, Yang Y, Huang C, Ge L, Wue L, Xiao Z,Xiao T, Zhao H, Ren P, Zhang J.V. Chemerin: afunctional adipokine in reproductive health anddiseases. Biomedicines. 2022; 10, 1910.

  13. Flores Le-Roux J.A, Benaiges Boix D, BotetMontoya J. P. Quemerina: una nuevaadipoquina. Clin Invest Arterioscl. 2011; 23(4):175-182.

  14. Fischer T.F, Beck-Sickinger A.G. Chemerin -exploring a versatile adipokine. Biol Chem.2022; 403(7):625-642.

  15. Yun H, Dumbell R, Hanna K, Bowen J, McleanS.L, Katamneni S, Pors K, Quin Feng W, HelferG.The chemerin-CMKLR1 axis is functionalimportant central regulation of energyhomeostasis. Front Physol. 2022; 13:897105.

  16. De Henau O, Degroot G.N, Imbault V, RobertV, De Poorter C, Mcheik S, Galés C, ParmentierM, Springael J.Y. Signaling Properties ofChemerin Receptors CMKLR1, GPR1 andCCRL2. PLoS One. 2016; 11(10):e0164179.

  17. Aguilera C, Labbé T, Busquets J, Venegas P,Neira C. Valenzuela A. Obesidad: ¿Factor deriesgos o enfermedad? Rev Med Chile. 2019;147:470-474.

  18. Organización Mundial de la Salud (OMS)[Internet]. Obesidad y sobrepeso. 2021. [citado15 ene 2023]. Disponible en:https://www.who.int/es/news-room/fact-sheets/detail/obesity-and-overweight

  19. Bello Chavolla O. Y. Fisiología del tejidoadiposo. Manual Moderno [Internet]. 2018.[citado 27 marzo 2023]. p: 1-11. Disponible en:https://www.researchgate.net/publication/329374990_Fisiologia_del_Tejido_Adiposo

  20. Sosa García B.C, Mendieta Zerón H, HinojosaJuárez A.C, García M.C. Quemerina, omentina-1 y miR-103p y su relación con la diabetesmellitus gestacional. Revista Colombiana deEndocrinología, Diabetes y Metabolismo.2020; 7(1):20-28.

  21. Sequeira Fontes V, Silva Neves F, CarlosCandido A. P. Chemerin and factors related tocardiovascular risk in children and adolescents:a systematic review. Rev Paul Pedriatr. 2018;36(2):221-229.

  22. Cajas Santana L.J, Rondón Herrera F, Rojas A,Martínez Lozano D, Prieto N, BohorquezCastañeda M. Quemerina sérica en una cohortede pacientes colombianos con osteoartritisprimaria. Reumatol Clin. 2021; 17(9):530-535.

  23. Hong-Jun Ba, Ling-Ling Xu, You-Zhen Qin,Hong-Shan Chen. Serum chemerin levelscorrelate with determinants of metabolicsyndrome in obese children and adolescents.Clinical Medicine Insights: Pediatrics. 2019; 13:1-5.

  24. Bezaoglu K, Bolton K, McMillan J, Zimmet P,Jowett J, Collier G, Walder K, Segal D.Chemerin is a novel adipokine associated withobesity and metabolic syndrome.Endocrinology. 2007; 148(10):4687-4694.

  25. Torres Courchound I, Pérez Calvo J. I.Biomarcadores y práctica clínica. An Sist SanitNavar. 2016; 39(1):5-8.

  26. Martí A, Martínez I, Ojeda-Rodríguez A,Azcona Sanjulian M. Higherlipopolysaccharide Binding protein andchemerin concentrations were associated withmetabolic syndrome features in pediatricsubjects with abdominal obesity during alifestyle intervention. Nutrients. 2021; 13:289.

  27. González-Ponce F, Gamez-Nava J. I, Pérez-Guerrero E. E, Saldaña-Cruz A. M, Vázquez-Villegas M. L, Ponce-Guarneros J. M, HuertaM, Trujillo X, Contreras Haro B, Rocha MuñozA.D, Carrillo Escalante M. O, SánchezRodríguez E. N, Gómez Ramírez E. E, NavaValdivia C. A, Cardona Muñoz E. G, GonzálezLópez L. Serum chemerin levels: A potentialbiomarker of join inflammation in women with

  28. rheumatoid arthritis. PLoS ONE. 2021;16(9):e0255854.

  29. Falah L, Yaseen A. Correlation of chemerinwith lipid profile in blood women polycysticovarian syndrome in Tikriti City. Medico-LegalUpdate. 2021; 21(2);392-397.

  30. Habib S.S, Eshki A, Altassan B, Fatani D,Helmi H, Alsaif S. Relationship of serum noveladipokine chemerin levels with bodycomposition, insulin resistance, dyslipidemiaand diabesity in saudi women. EuropeanReview for Medical and PharmacologicalSciences. 2017; 21(6);1296-1302.

  31. Chang S.S, Eisenberg D, Zhao L, Adams C,Leib R, Morser J, Leung L. Chemerin activationin human obesity. Obesity. 2016; 24:1522-1529.




2020     |     www.medigraphic.com